Base de dados : MEDLINE
Pesquisa : D02.241.081.251.203 [Categoria DeCS]
Referências encontradas : 99 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10 ir para página                        

  1 / 99 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311445
[Au] Autor:Somura Y; Kimoto K; Oda M; Okutsu Y; Kato R; Suzuki Y; Siki D; Hirai A; Akiba T; Shinkai T; Sadamasu K
[Ad] Endereço:Tokyo Metropolitan Institute of Public Health.
[Ti] Título:[Serial Food Poisoning Outbreaks Caused by Norovirus-Contaminated Shredded Dried Laver Seaweed Provided at School Lunch, Tokyo, 2017].
[So] Source:Shokuhin Eiseigaku Zasshi;58(6):260-267, 2017.
[Is] ISSN:1882-1006
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:In February 2017, four food poisoning outbreaks occurred in Tokyo, involving ten schools. Shredded dried laver seaweed processed by a single food manufacturer in December 2016 was provided in common for the school meals that caused all four outbreaks. Of 4,209 persons exposed, 1,193 (28.3%) had symptoms of gastroenteritis. Norovirus (NoV) GII was detected in 207 (78.1%) of 265 cases by real-time RT-PCR. Thirty-one shredded dried laver seaweed samples were examined and seven (22.6%) of them were positive for NoV GII. PCR fragments of NoV ORF1/2 junction region (302 bp) from seven shredded dried laver seaweed samples and 20 clinical samples derived from the four outbreaks were sequenced. All of them displayed complete homology, and the genotype was classified as GII.17. A nearly full-length sequence (7,420 bp) of NoV RNA derived from a case was obtained by next-generation sequencer analysis and phylogenetic analysis indicated that this strain belongs to the same cluster as Hu/GII/JP/2015/GII.P17_GII.17/Kawasaki308. Thus, our investigation elucidated that the causative agent of these four serial food poisoning outbreaks was NoV GII.17 and the infectious source was a single batch of shredded dried laver seaweed. The water activity of the shredded dried laver seaweed was found to be 0.119 to 0.129. It was epidemiologically clarified that NoV does not lose infectivity for about two months even in the dry state. We conclude that a large diffuse outbreak of food poisoning caused by NoV GII.17 contamination of shredded dried laver seaweed had occurred in Tokyo. Our elucidation of the causative agent indicated that the food poisoning outbreaks in multiple areas of Japan, including Tokyo, during January to February 2017 were caused by the same contaminated food.
[Mh] Termos MeSH primário: Infecções por Caliciviridae/etiologia
Infecções por Caliciviridae/virologia
Surtos de Doenças/estatística & dados numéricos
Análise de Alimentos
Contaminação de Alimentos/análise
Doenças Transmitidas por Alimentos/etiologia
Doenças Transmitidas por Alimentos/virologia
Almoço
Norovirus/isolamento & purificação
Instituições Acadêmicas/estatística & dados numéricos
Alga Marinha/virologia
[Mh] Termos MeSH secundário: Infecções por Caliciviridae/epidemiologia
Cobicistat
Combinação de Medicamentos
Emtricitabina
Doenças Transmitidas por Alimentos/epidemiologia
Norovirus/classificação
Norovirus/genética
Quinolonas
RNA Viral/isolamento & purificação
Tenofovir/análogos & derivados
Fatores de Tempo
Tóquio/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Quinolones); 0 (RNA, Viral); 0 (genovoya); 99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.3358/shokueishi.58.260


  2 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632758
[Au] Autor:Squillace N; Ricci E; Quirino T; Gori A; Bandera A; Carenzi L; De Socio GV; Orofino G; Martinelli C; Madeddu G; Rusconi S; Maggi P; Celesia BM; Cordier L; Vichi F; Calza L; Falasca K; Di Biagio A; Pellicanò GF; Bonfanti P; CISAI Study Group
[Ad] Endereço:Infectious Diseases Clinic, Azienda Socio Sanitaria Territoriale di MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy.
[Ti] Título:Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
[So] Source:PLoS One;12(6):e0179254, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The study aim was to evaluate the impact on Liver and Kidney toxicity of the single tablet regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF) on Antiretroviral Therapy (ART) experienced or naïve patients. METHODS: Patients initiating EVG/COBI/FTC/TDF were enrolled in the SCOLTA project, a multicenter observational study reporting grade 3-4 Adverse Events in subjects beginning new antiretroviral drug regimens. In this analysis, patients were evaluated at T0 (baseline), T1 (six months) and at T2 (twelve months). RESULTS: A total of 329 patients were enrolled, and 280 (85.1%) of these had at least one follow-up visit. Median observation time was 11 months (IQR 7.0-15.5). Two hundred and two patients (72.1%) were ART experienced and 78 (27.9%) ART naive. Prevalence of HCV-co-infection was 21.4%. At T1, we observed a significant decline in estimated glomerular filtration rate (eGFR), both in experienced and naive patients (mean change from T0-7.5 ± 12.8 ml/min, -15.5 ± 17.8 ml/min, respectively, p = 0.0005), which was confirmed at T2 (mean change from T0-8.2 ± 15.8 ml/min, -17.6 ± 19.4 ml/min, respectively, p = 0.001). Regarding aspartate aminotransferase (AST) and alanine transaminase (ALT) grade 1-2 modifications, no significant differences were observed between experienced and naïve subjects, but an increased prevalence of abnormal liver function test was observed in patients with chronic HCV infection (p<0.001). CONCLUSIONS: A significant decline in eGFR was observed in patients initiating EVG/COBI/FTC/TDF in the first 6 months, with no significant worsening occurring at 12 months vs. 6 months of therapy. Patients with chronic HCV infection were at higher risk to develop abnormal liver tests.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Cobicistat/uso terapêutico
Emtricitabina/uso terapêutico
Infecções por HIV/tratamento farmacológico
HIV-1/efeitos dos fármacos
Quinolonas/uso terapêutico
Tenofovir/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Combinação de Medicamentos
Feminino
Infecções por HIV/virologia
Seres Humanos
Masculino
Dose Máxima Tolerável
Meia-Idade
Segurança
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Drug Combinations); 0 (JTK 303); 0 (Quinolones); 99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179254


  3 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28282300
[Au] Autor:Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
[Ad] Endereço:*Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario La Paz, Madrid, ES; †AIDS Research Consortium of Atlanta, Atlanta, GA; ‡Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; §Internal Medicine, General Hospital Graz-West, Graz, AT; ‖Tarrant County Infectious Disease Associates, Fort Worth, TX; ¶Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC; #Orlando Immunology Center, Orlando, FL; **Claude Nicol Centre, Royal Sussex County Hospital, Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom; and ††Departments of Biometrics, Virology, Clinical Operations, and HIV Clinical Research, Gilead Sciences, Inc., Foster City, CA.
[Ti] Título:Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
[So] Source:J Acquir Immune Defic Syndr;75(2):211-218, 2017 Jun 01.
[Is] ISSN:1944-7884
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In 2 double-blind phase 3 trials, 1733 antiretroviral-naive adults were randomized to tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 144 weeks, TAF was superior to TDF in virologic efficacy, with 84.2% vs 80.0% having HIV-1 RNA <50 copies/mL (difference 4.2%; 95% confidence interval: 0.6% to 7.8%). TAF had less impact than TDF on bone mineral density and renal biomarkers. No participants on TAF had renal-related discontinuations vs 12 on TDF (P < 0.001), with no cases of proximal tubulopathy for TAF vs 4 for TDF. There were greater increases in lipids with TAF vs TDF, with no difference in the total cholesterol to high-density lipoprotein ratio. For initial HIV therapy, E/C/F/TAF is superior to E/C/F/TDF in efficacy and bone and renal safety.
[Mh] Termos MeSH primário: Adenina/análogos & derivados
Fármacos Anti-HIV/uso terapêutico
Cobicistat/uso terapêutico
Emtricitabina/uso terapêutico
Infecções por HIV/tratamento farmacológico
Quinolonas/uso terapêutico
Tenofovir/uso terapêutico
[Mh] Termos MeSH secundário: Adenina/uso terapêutico
Densidade Óssea/efeitos dos fármacos
Contagem de Linfócito CD4
Método Duplo-Cego
Infecções por HIV/imunologia
Seres Humanos
Meia-Idade
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (GS-7340); 0 (JTK 303); 0 (Quinolones); 99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine); JAC85A2161 (Adenine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170623
[Lr] Data última revisão:
170623
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE
[do] DOI:10.1097/QAI.0000000000001350


  4 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219799
[Au] Autor:Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
[Ad] Endereço:University of Turin, Department of Medical Sciences,(2) Laboratory of Clinical Pharmacology and Pharmacogenetics,(3) Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy; "CoQuaLab", Academic Apin-off of University of Turin, Italy.
[Ti] Título:UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
[So] Source:J Pharm Biomed Anal;138:223-230, 2017 May 10.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8µm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.
[Mh] Termos MeSH primário: Antirretrovirais/sangue
Antirretrovirais/química
Cromatografia Líquida de Alta Pressão/métodos
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Fármacos Anti-HIV/sangue
Fármacos Anti-HIV/química
Cobicistat/sangue
Cobicistat/química
Compostos Heterocíclicos com 3 Anéis/sangue
Compostos Heterocíclicos com 3 Anéis/química
Seres Humanos
Limite de Detecção
Quinolonas/sangue
Quinolonas/química
Reprodutibilidade dos Testes
Rilpivirina/sangue
Rilpivirina/química
Ritonavir/sangue
Ritonavir/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Anti-Retroviral Agents); 0 (Heterocyclic Compounds, 3-Ring); 0 (JTK 303); 0 (Quinolones); DKO1W9H7M1 (dolutegravir); FI96A8X663 (Rilpivirine); LW2E03M5PG (Cobicistat); O3J8G9O825 (Ritonavir)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  5 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28186251
[Au] Autor:Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
[Ad] Endereço:IAME, UMR 1137, Univ. Paris Diderot, Sorbonne Paris Cité, Paris F-75018, France.
[Ti] Título:Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
[So] Source:J Antimicrob Chemother;72(6):1745-1751, 2017 Jun 01.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as a single-tablet regimen (STR) using the PCR signal of the plasma viral load (pVL) assay and determination of plasma drug concentration ( C 24 ). Patients and methods: This was an observational single-centre study enrolling antiretroviral-treated patients with pVL <50 copies/mL initiating elvitegravir-based STR. PCRneg was defined as an undetected PCR signal. Results: One hundred and fifty-one patients were enrolled. At STR baseline, the median time since first ART and time of virological suppression were 5 years (IQR 3-9) and 24 months (IQR 9-44), respectively. By week (W) 48, 26 (17%) of the patients had discontinued STR due to adverse events. The proportion of patients maintaining pVL <50 copies/mL on treatment was 98%, 96%, 93% and 97% at W12, W24, W36 and W48, respectively. Five patients (3.3%) experienced a virological failure and emergence of resistance was observed in two of them with the selection of M184V and N155H mutations. At baseline, W12, W24, W36 and W48, 70%, 57%, 72%, 61% and 74% of the patients with pVL <20 copies/mL had a PCRneg, respectively. The median elvitegravir plasma C 24 value was 648 ng/mL (IQR 348-989; n = 237), with 84% of elvitegravir C 24 values >45 ng/mL, the protein-adjusted IC 95 . Conclusions: In this clinical cohort of virologically suppressed patients switching to STR, most subjects had adequate elvitegravir C 24 values with a high proportion maintaining virological suppression with no residual viraemia until W48.
[Mh] Termos MeSH primário: Cobicistat/uso terapêutico
Emtricitabina/uso terapêutico
Infecções por HIV/tratamento farmacológico
Quinolonas/uso terapêutico
Tenofovir/uso terapêutico
Carga Viral
[Mh] Termos MeSH secundário: Adulto
Fármacos Anti-HIV/administração & dosagem
Fármacos Anti-HIV/sangue
Fármacos Anti-HIV/uso terapêutico
Terapia Antirretroviral de Alta Atividade
Contagem de Linfócito CD4
Cobicistat/administração & dosagem
Cobicistat/sangue
Estudos de Coortes
Emtricitabina/administração & dosagem
Emtricitabina/sangue
Feminino
Infecções por HIV/sangue
HIV-1/efeitos dos fármacos
Seres Humanos
Quimioterapia de Manutenção
Masculino
Meia-Idade
Reação em Cadeia da Polimerase
Quinolonas/administração & dosagem
Quinolonas/sangue
RNA Viral/sangue
Comprimidos
Tenofovir/administração & dosagem
Tenofovir/sangue
Viremia/tratamento farmacológico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (JTK 303); 0 (Quinolones); 0 (RNA, Viral); 0 (Tablets); 99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dkx018


  6 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166190
[Au] Autor:Jongbloed-de Hoon M; Colbers A; Velthoven-Graafland K; Duisenberg-van Essenberg M; Kruijssen M; Abbink E; van Crevel R; Burger D
[Ad] Endereço:*Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands; †Department of Pharmacy, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands; ‡Clinical Research Centre Nijmegen, Radboud University Medical Center, Nijmegen, the Netherlands; and §Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
[Ti] Título:Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.
[So] Source:J Acquir Immune Defic Syndr;74(5):571-574, 2017 Apr 15.
[Is] ISSN:1944-7884
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We investigated whether a fixed-dose combination tablet of elvitegravir, cobicistat, emtricitabine, and tenofovirDF (Stribild) can be crushed and combined with enteral nutrition without influencing pharmacokinetics. This was an open-label, 3-period, single-dose, randomized, crossover trial in 24 healthy volunteers. Subjects received Stribild whole tablet with breakfast (reference), crushed/suspended Stribild + breakfast, crushed/suspended Stribild + enteral nutrition. Crushed/suspended Stribild + enteral nutrition was bioequivalent (90% confidence interval between 80% and 125%) with a whole Stribild tablet. Crushed/suspended Stribild + breakfast showed bioequivalence for the area under the curve (AUC0-32), but not for maximum concentration (Cmax) (considered not clinically relevant). Patients with swallowing difficulties or an enteral feeding tube can use crushed and suspended Stribild tablets.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/administração & dosagem
Fármacos Anti-HIV/farmacocinética
Nutrição Enteral
Quinolonas/administração & dosagem
Quinolonas/farmacocinética
Comprimidos/administração & dosagem
Comprimidos/farmacocinética
[Mh] Termos MeSH secundário: Adenina/administração & dosagem
Adenina/análogos & derivados
Adenina/farmacocinética
Adulto
Cobicistat/administração & dosagem
Cobicistat/farmacocinética
Estudos Cross-Over
Emtricitabina/administração & dosagem
Emtricitabina/farmacocinética
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
Meia-Idade
Ácidos Fosforosos/administração & dosagem
Ácidos Fosforosos/farmacocinética
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine); 0 (Anti-HIV Agents); 0 (JTK 303); 0 (Phosphorous Acids); 0 (Quinolones); 0 (Tablets); G70B4ETF4S (Emtricitabine); JAC85A2161 (Adenine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1097/QAI.0000000000001296


  7 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27999051
[Au] Autor:Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Llaves S; Fernandez-Magdaleno T; Espinosa N; Viciana P; Lopez-Cortes LF
[Ti] Título:Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
[So] Source:J Antimicrob Chemother;72(3):816-819, 2017 Mar 01.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: To evaluate if there are significant drug-drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously. Methods: The study population consisted of three groups of unselected volunteers taking a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (150, 150, 200 and 300 mg, respectively) co-formulated in a single tablet plus 800 mg darunavir (group A); only co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (group B); and cobicistat-boosted darunavir (800 mg darunavir + 150 mg cobicistat) plus two nucleos(t)ide analogues (group C). Elvitegravir, cobicistat and darunavir concentrations at the end of the dosing interval ( C 24 ) were quantified using a validated LC with tandem MS method. Results: A total of 170 samples were obtained from 24, 32 and 32 patients in groups A, B and C, respectively. In group A, the elvitegravir C 24 were similar to those in group B (233.67 versus 250.39 ng/mL) ( P = 0.406) and the darunavir C 24 were similar to those in group C (1293.54 versus 1319.34 ng/mL) ( P = 0.908). The cobicistat C 24 were comparable in groups A and B (20.2 versus 20.9 ng/mL) and slightly higher in group C (27.7 ng/mL) ( P = 0.059). Conclusions: The results provide evidence of similar elvitegravir and darunavir C 24 concentrations when these drugs are co-administered as co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir or dosed separately.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacocinética
Cobicistat/administração & dosagem
Darunavir/farmacocinética
Infecções por HIV/tratamento farmacológico
Quinolonas/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Fármacos Anti-HIV/administração & dosagem
Fármacos Anti-HIV/uso terapêutico
Cobicistat/uso terapêutico
Darunavir/administração & dosagem
Darunavir/uso terapêutico
Combinação de Medicamentos
Interações Medicamentosas
Feminino
Infecções por HIV/virologia
HIV-1/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
Quinolonas/administração & dosagem
Quinolonas/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Drug Combinations); 0 (JTK 303); 0 (Quinolones); LW2E03M5PG (Cobicistat); YO603Y8113 (Darunavir)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dkw487


  8 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27798211
[Au] Autor:Smolders EJ; Colbers EP; de Kanter CT; Velthoven-Graafland K; Drenth JP; Burger DM
[Ad] Endereço:Department of Pharmacy, Radboud Institute for Health Sciences (RHIS) and Radboud University Medical Center, Nijmegen, The Netherlands elise.smolders@radboudumc.nl.
[Ti] Título:Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
[So] Source:J Antimicrob Chemother;72(2):486-489, 2017 Feb.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir. When combined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced from 60 to 30 mg once daily. Recently, cobicistat was licensed as a CYP3A booster and used with atazanavir. OBJECTIVES: To determine whether the fixed-dose combination of atazanavir/cobicistat has an influence on daclatasvir pharmacokinetics comparable to that of the separate agents atazanavir and ritonavir. METHODS: A prospective, open-label, two-period, randomized, cross-over trial was performed in 16 healthy subjects (NCT02565888). Treatment consisted of 300/100 mg of atazanavir/ritonavir plus 30 mg of daclatasvir once daily (reference) and a second period of 300/150 mg of atazanavir/cobicistat plus 30 mg of daclatasvir once daily (test). A 24 h pharmacokinetic, steady-state curve was recorded for all drugs. Geometric mean ratios (GMRs) with 90% CI were calculated for daclatasvir and atazanavir AUC and C to compare the effect of both treatments (test versus reference). Laboratory safety and adverse events were evaluated throughout the trial. RESULTS: All 16 healthy subjects completed the study. Median (range) age and BMI were 48.5 (21-55) years and 24.5 (19.0-29.2) kg/m , respectively. Pharmacokinetic parameters of ritonavir and cobicistat were comparable to those in the literature. The GMRs (90% CI) of daclatasvir AUC and C (test versus reference) were 101% (92%-111%) and 97% (89%-106%), respectively. Atazanavir GMRs (90% CI) of AUC and C were 82% (75%-79%) and 74% (68%-81%), respectively. No serious adverse events were reported. CONCLUSIONS: Atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on daclatasvir pharmacokinetics in healthy volunteers. Daclatasvir at 30 mg once daily is the correct dose when combined with atazanavir/cobicistat.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Sulfato de Atazanavir/uso terapêutico
Cobicistat/uso terapêutico
Infecções por HIV/tratamento farmacológico
Imidazóis/administração & dosagem
Imidazóis/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Fármacos Anti-HIV/efeitos adversos
Fármacos Anti-HIV/farmacocinética
Sulfato de Atazanavir/farmacocinética
Cobicistat/farmacocinética
Estudos Cross-Over
Inibidores do Citocromo P-450 CYP3A/farmacocinética
Inibidores do Citocromo P-450 CYP3A/uso terapêutico
Feminino
Seres Humanos
Imidazóis/farmacocinética
Masculino
Meia-Idade
Estudos Prospectivos
Ritonavir/farmacocinética
Ritonavir/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (BMS-790052); 0 (Cytochrome P-450 CYP3A Inhibitors); 0 (Imidazoles); 4MT4VIE29P (Atazanavir Sulfate); LW2E03M5PG (Cobicistat); O3J8G9O825 (Ritonavir)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dkw429


  9 / 99 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27190354
[Au] Autor:Milburn J; Jones R; Levy JB
[Ad] Endereço:Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Du Cane Road, London, UK.
[Ti] Título:Renal effects of novel antiretroviral drugs.
[So] Source:Nephrol Dial Transplant;32(3):434-439, 2017 03 01.
[Is] ISSN:1460-2385
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic kidney disease (CKD) is a critical comorbidity for patients living with HIV, with an estimated prevalence between 2.4 and 17%. Such patients are increasingly affected by diseases associated with ageing, including cardiovascular disease and CKD, and the prevalence of risk factors such as smoking and dyslipidaemia is increased in this population. Proteinuria is also now recognized as a common finding in individuals living with HIV. While combination antiretroviral (ARV) treatments reduce CKD in the HIV-infected population overall, some ARV drugs have been shown to be nephrotoxic and associated with worsening renal function. Over the last few years, several highly efficacious new ARV agents have been introduced. This brief review will look at the novel agents dolutegravir, raltegravir, elvitegravir, cobicistat, tenofovir alafenamide fumarate and atazanavir, all of which have been licensed relatively recently, and describe issues relevant to renal function, creatinine handling and potential nephrotoxicity. Given the prevalence of CKD, the wide range of possible interactions between HIV, ARV therapy, CKD and its treatments, nephrologists need to be aware of these newer agents and their possible effect on kidneys.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/efeitos adversos
Infecções por HIV/tratamento farmacológico
Insuficiência Renal Crônica/induzido quimicamente
[Mh] Termos MeSH secundário: Adenina/efeitos adversos
Adenina/análogos & derivados
Sulfato de Atazanavir/efeitos adversos
Cobicistat/efeitos adversos
Creatinina
Progressão da Doença
Infecções por HIV/complicações
Compostos Heterocíclicos com 3 Anéis/efeitos adversos
Seres Humanos
Proteinúria/induzido quimicamente
Proteinúria/complicações
Quinolonas/efeitos adversos
Raltegravir Potássico/efeitos adversos
Insuficiência Renal Crônica/complicações
Insuficiência Renal Crônica/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (GS-7340); 0 (Heterocyclic Compounds, 3-Ring); 0 (JTK 303); 0 (Quinolones); 43Y000U234 (Raltegravir Potassium); 4MT4VIE29P (Atazanavir Sulfate); AYI8EX34EU (Creatinine); DKO1W9H7M1 (dolutegravir); JAC85A2161 (Adenine); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE
[do] DOI:10.1093/ndt/gfw064


  10 / 99 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27894270
[Au] Autor:Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
[Ad] Endereço:Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France. nadia.valin@aphp.fr.
[Ti] Título:Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
[So] Source:BMC Infect Dis;16(1):718, 2016 Nov 29.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The preferred regimen for HIV post-exposure prophylaxis (PEP) is based mainly on safety and tolerability because it is given to immunocompetent people without HIV infection for a limited time (28 days). The frequency of adverse events (AEs) may be > 60%. Although AEs are generally not severe, they can lead to lack of adherence and failure to complete the regimen. We evaluated the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild ) prescribed as one pill taken once daily for HIV PEP in terms of tolerability and adherence. METHODS: This was a prospective cohort study conducted in one hospital in Paris (April to December 2015. Each participant receiving the PEP treatment (FTC-150 mg/TDF-245 mg/elvitegravir-200 mg/cobicistat 150 mg once daily) at the pharmacy of the hospital were recruited consecutively. A clinical visit was planned at 8 weeks after sexual exposure. Reminders were sent to participants who missed the appointment. A standardized questionnaire was administered to evaluate completeness and tolerability at week 8. RESULTS: Overall, 284 participants (86% men; 80% MSM; median age 30 years) were prescribed Stribild ; 50 stopped after reassessment of risk. Among 234 participants who effectively received PEP, 215 (92%) completed 28 days of PEP with only three who switched from Stribild to another PEP because of side effects. More than 60% of participants reported at least one AE, which were mild to moderate. Fatigue, central neurological and abdominal side effects were the most frequently reported. CONCLUSIONS: Stribild seems to be a good option for HIV PEP due to the easiness of use, the side effects profile and the high completion rate.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/efeitos adversos
Fármacos Anti-HIV/uso terapêutico
Combinação Elvitegravir, Cobicistat, Emtricitabina e Fumarato de Tenofovir Desoproxila/uso terapêutico
Infecções por HIV/prevenção & controle
Profilaxia Pós-Exposição/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Fármacos Anti-HIV/administração & dosagem
Cobicistat
Combinação de Medicamentos
Combinação Elvitegravir, Cobicistat, Emtricitabina e Fumarato de Tenofovir Desoproxila/administração & dosagem
Combinação Elvitegravir, Cobicistat, Emtricitabina e Fumarato de Tenofovir Desoproxila/efeitos adversos
Feminino
Infecções por HIV/tratamento farmacológico
Homossexualidade Masculina
Seres Humanos
Masculino
Adesão à Medicação
Meia-Idade
Paris
Estudos Prospectivos
Comportamento Sexual
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Drug Combinations); 0 (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination); LW2E03M5PG (Cobicistat)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170612
[Lr] Data última revisão:
170612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161130
[St] Status:MEDLINE



página 1 de 10 ir para página                        
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde